Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Yong Wang, Xiangji Meng, Shizhen Zhou, Yufang Zhu, Jun Xu & Rongjie Tao. (2019) Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study. OncoTargets and Therapy 12, pages 10579-10585.
Read now
Read now
Dongdong Yu, Guang Han, Huali Liu, Likun Gao & Vivek Verma. (2019) Treatment of adult brainstem glioma with combined antiangiogenic therapy: a case report and literature review. OncoTargets and Therapy 12, pages 1333-1339.
Read now
Read now
Articles from other publishers (21)
Jiayi Huang, Xiao Chen, Jinfeng Guo, Lin Song, Yanxi Mu, Han Zhao & Caiwen Du. (2022) Apatinib combined with trastuzumab and albumin‑bound paclitaxel for treatment of HER2+ breast cancer with brain metastases resistant to anti‑HER2 TKIs: A case report. Oncology Letters 25:2.
Crossref
Crossref
Ming Zhang, Liying Gao, Xiaofeng Liu, Fang Dong, Qun Su, Yanping Zhang, Fengju Li, Hulan Wang & Pengbing Han. (2022) Low-Dose Apatinib Improves the Prognosis of Patients with Recurrent High-Grade Gliomas. Evidence-Based Complementary and Alternative Medicine 2022, pages 1-6.
Crossref
Crossref
Hong-Hong Zhang, Xiao-Jing Du, Mei-Ling Deng, Lie Zheng, Dun-Chen Yao, Zhi-Qiang Wang, Qun-Ying Yang & Shao-Xiong Wu. (2022) Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option. Frontiers in Pharmacology 13.
Crossref
Crossref
Liang Xia, Mingjie Gong, Yangfan Zou, Zeng Wang, Bin Wu, Shuyuan Zhang, Liwen Li, Kai Jin & Caixing Sun. (2022) Apatinib Induces Ferroptosis of Glioma Cells through Modulation of the VEGFR2/Nrf2 Pathway. Oxidative Medicine and Cellular Longevity 2022, pages 1-15.
Crossref
Crossref
Hang-Ping Wei, Jie Mao & Zu-Liang Hu. (2022) Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report. World Journal of Clinical Cases 10:11, pages 3593-3600.
Crossref
Crossref
Fuhua Lin, Chengcheng Guo, Qunying Yang, Yinsheng Chen, Chao Ke, Ke Sai, Ji Zhang, Xiaobing Jiang, Wanming Hu, Shaoyan Xi, Jian Zhou, Depei Li, Zhihuan Zhou, Qinqin Zhao, Xi Cao & Zhong-ping Chen. (2022) Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study. Glioma 5:1, pages 29.
Crossref
Crossref
Hui Yao, Jiangang Liu, Chi Zhang, Yunxiang Shao, Xuetao Li, Zhengquan Yu & Yulun Huang. (2021) Apatinib inhibits glioma cell malignancy in patient-derived orthotopic xenograft mouse model by targeting thrombospondin 1/myosin heavy chain 9 axis. Cell Death & Disease 12:10.
Crossref
Crossref
Gabriel Emilio Herrera-Oropeza, Carla Angulo-Rojo, Santos Alberto Gástelum-López, Alfredo Varela-Echavarría, Maribel Hernández-Rosales & Katia Aviña-Padilla. (2021) Glioblastoma multiforme: a multi-omics analysis of driver genes and tumour heterogeneity. Interface Focus 11:4.
Crossref
Crossref
Hui Yao, Jiangang Liu, Chi Zhang, Yunxiang Shao, Xuetao Li, Ming Feng, Ximing Wang, Wenjuan Gan, Youxin Zhou & Yulun Huang. (2021) Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas. Journal of Clinical Neuroscience 90, pages 82-88.
Crossref
Crossref
Zheng Chen, Xiangyu Wei, Xueyi Wang, Xuan Zheng, Bowen Chang, Lin Shen, Hanshuo Zhu, Min Yang, Shiting Li & Xuesheng Zheng. (2021) NDUFA4L2 promotes glioblastoma progression, is associated with poor survival, and can be effectively targeted by apatinib. Cell Death & Disease 12:4.
Crossref
Crossref
Jun-Hui Guo, Yuan-Yuan Wang, Jiang-Wei Zhang, Pei-Min Liu, Yan-Jun Hao & Hai-Rui Duan. (2020) Clinical effects of apatinib mesylate for treatment of multiple brain micrometastases: Two case reports. World Journal of Clinical Cases 8:7, pages 1326-1336.
Crossref
Crossref
Na Wang, Shubo Chen, Dengxiang Liu, Jun Guo, Yawei Sun, Juping Zhang, Qian Kong & Lili He. (2020) Therapeutic effect of small molecule targeting drug apatinib on gastric cancer and its role in prognosis and anti-infection mechanism. Saudi Journal of Biological Sciences 27:2, pages 606-610.
Crossref
Crossref
Haozhe Piao, Ye Zhang, Chengcheng Guo, Li Zhu, Linan Liu, Ulrich Herrlinger, Felix Sahm & Zhong-ping Chen. (2020) East meets West for the treatment of glioma: A discussion of real-world cases. Glioma 3:1, pages 24.
Crossref
Crossref
Zhong-ping Chen. (2019) Anti-angiogenic therapy for glioma: Puzzle and hope. Glioma 2:4, pages 182.
Crossref
Crossref
Zedong Du, Yanxin Yu, Dajun Wu, Guangyu Zhang, Yang Wang, Liang He & RongQin Meng. (2018) Apatinib for salvage treatment of advanced malignant pleural mesothelioma. Medicine 97:45, pages e13105.
Crossref
Crossref
Xiaofeng Li, Yueming He, Jinfeng Zhu, Hongxia Pang, Yongwei Lin & Jinyang Zheng. (2018) Apatinib-based targeted therapy against pulmonary sarcomatoid carcinoma: a case report and literature review. Oncotarget 9:72, pages 33734-33738.
Crossref
Crossref
Ting Hu, Cuiwei Liu, Qiuhui Li, Jie Xiong, Yuxi Ma, Gang Wu & Yanxia Zhao. (2018) Apatinib + CPT-11 + S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer. Medicine 97:15, pages e0349.
Crossref
Crossref
Miaomiao Gou, Haiyan Si, Yong Zhang, Niansong Qian, Zhikuan Wang, Weiwei Shi & Guanghai Dai. (2018) Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study. Scientific Reports 8:1.
Crossref
Crossref
Xiaoyun Liu, Yifan Zhang, Qian Chen, Yan Zhan, Quanren Wang, Chaoying Hu, Chen Yu, Zitao Guo, Xiaoyan Chen & Dafang Zhong. (2017) Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole. The Journal of Clinical Pharmacology 58:3, pages 347-356.
Crossref
Crossref
Yong Zhou, Fan Tang, Yiying Wang, Li Min, Yi Luo, Wenli Zhang, Rui Shi, Hong Duan & Chongqi Tu. (2017) Advanced alveolar soft part sarcoma responds to apatinib. Oncotarget 8:30, pages 50314-50322.
Crossref
Crossref
. (2017) Apatinib. Reactions Weekly 1650:1, pages 47-47.
Crossref
Crossref